Company / Cash & Equivalents
Evolent Health, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$151.9M
FY2025
5-year range
$104.2M / $266.3M
FY2021-FY2025
Trend
+45.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $101M in FY2019 to $319M in FY2020.
Based on SEC 10-K filings.
$152M in FY2025 with a 5-year CAGR of -13.8%.
Declined from $193M to $152M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -6.9%
- 5-Year CAGR
- -13.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -13.8%, indicating a declining trend.
- In FY2025, cash & equivalents increased 45.7% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
- Lowest cash & equivalents in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -0.84 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $151.9M | +45.7% |
| FY2024 | $104.2M | -46.0% |
| FY2023 | $192.8M | +2.5% |
| FY2022 | $188.2M | -29.3% |
| FY2021 | $266.3M | -16.5% |
| FY2020 | $319.0M | +215.8% |
| FY2019 | $101.0M | -55.8% |
| FY2018 | $228.3M | -4.2% |
| FY2017 | $238.4M | +77.2% |
| FY2016 | $134.6M | -7.7% |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026